воскресенье, 10 февраля 2008 г.

Incretin hormone mimetics and analogues in diabetes therapeutics.

PubMed Result A service of the and the Search PubMedProteinNucleotideCoreNucleotideGSSESTStructureGenomeBooksCancerChromosomesConserved DomainsdbGaP3D DomainsGeneGenome ProjectGENSATGEO ProfilesGEO DataSetsHomoloGeneJournalsMeSHNCBI Web SiteNLM CatalogOMIAOMIMPMCPopSetProbeProtein ClustersPubChem BioAssayPubChempoundPubChem SubstanceSNPTaxonomyToolKitUniGeneUniSTS for GO CLEAR , .Biological Sciences, Queens University Belfast, David Keir Building, Stranmillis Road, Belfast BT6 0NJ, Northern Ireland, UK.Hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and extrapancreatic glucoregulatory actions.Analogues/mimetics activate GLP-1 or GIP receptors whilst avoiding physiological inactivation by dipeptidyl peptidase 4 (DPP-4), and they represent one of the newest classes of antidiabetic drug.First clinically approved GLP-1 mimetic for the treatment of type-2 diabetes is exenatide (Byetta/exendin) which is administered subcutaneously twice daily.Trials of liraglutide, a GLP-1 analogue suitable for once-daily administration, are ongoing.Number of other incretin molecules are at earlier stages of development.Review discusses the various attributes of GLP-1 and GIP for diabetes treatment and summarises current clinical data.
Read more Amoxicillin and clavulanate potassium (amoxicillin and clavulanate potassium) tablet, film coated [lek pharmaceuticals inc.]
Get more Triamcinolone: retinal pigment epithelial tear in an elderly patient following intravitreal administration: case report